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Objectives: To determine the significance ofprostaglandin 12(PGIO production by medial smooth muscle cells (SMCs), 
we assessed PGI 2 production from denuded vein grafts and their antithrombogenicity. 
Materials and Methods: A total of 30 dogs were divided into two groups: in group L 14 dogs (27 veins, 188 segments) 
were used to assay PGI 2 production, which was measured as 6-keto-PGF1L In group II, 16 dogs were used for an 
implantation study and the thrombus-free surface (TFS) score was calculated 24 h after implantation. Both groups 
contained the following subgroups: subgroup A, freshly harvested veins; subgroup B, endothelial denuded veins; subgroup 
C, veins frozen and cryopreserve& subgroup D, veins treated with protease. 
Results: Values of 6-keto-PGF ~ (pg/mg/min) forbasal and stimulated states in subgroup I-A through I-D were 58.0 ± 8.9 
and 530.6++_74.7, 26.3+4.7 and 82.3+11.4, 17.94-1.3 and 39.4+3.3, and 13.3+_1.8 and 32.2+_6.2, respectively. The 
PGI 2 production in subgroup I-A were significantly higher than those in the other three subgroups (p<O.01 for basal and 
stimulated), while the production in subgroup I-B was also significantly higher than those in the remaining two (p<O.05 
for basal and stimulated). TheTFS scores in subgroup II-A through II-D were 98 ± 2%, 90 ± 2%, 38 ± 5%, and 15 ± 7%, 
respectively, showing significantly superior antithrombogenicity in subgroup II-B, as well as in II-A, when compared 
with the remaining two (p= 0.014). 
Conclusion: The amount of PGF generated by the medial SMCs may be sufficient for maintaining the antithrombogenicity 
of the endothelial denuded A VGs. 
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Introduction 
Autogenous vein grafts (AVG) show excellent anti- 
thrombogenicity and patency, and have been widely 
used for bypasses to small calibre arteries. It has been 
considered that the optimal techniques for preparation 
of AVGs are effective in reducing the area of endo- 
thelial desquamation and preserving the functional 
integrity of medial smooth muscle cells (SMCs). Cam- 
bria et aI} reported that endothelial denuded areas at 
24 h after grafting were reduced to an average of about 
25% in non-distended reversed veins, and 15% in in 
situ vein grafts, respectively. However, our studies of 
endothelial denuded areas for 7 consecutive days after 
implantation, using stereomicroscopic scanning along 
the entire length of the graft flow surface, dem- 
onstrated that denuded areas in most AVGs reached 
a maximum level at 2 days, and occupied about 80% 
of the total area. These results were not related to the 
*Please address all correspondence and reprint requests to: 
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College, Nisikagura 4-5, Asahikawa 078, Japan. 
preparation techniques or the extent of endothelial 
coverage area immediately before implantation} 
Nevertheless, most of these extensively denuded AVGs 
showed excellent patency, regardless of the levels of 
the maximum denudation, suggesting the anti- 
thrombogenic benefit of the medial SMCs. The ob- 
jective of this study was to determine the significance 
of prostaglandin 12 (PGI 2) production by the medial 
SMCs in the antithrombogenicity of the endothelial 
denuded AVGs. To the authors' knowledge, there have 
been few reports 3"4 which have focused irectly on the 
function of the medial SMCs in AVGs. 
Materials and Methods 
Thirty randomly selected mongrel dogs of both sexes, 
weighing 11-21 kg (average 14.4 + 0.58 kg), were used 
in this study. Their care and use complied with the 
"Principles of Laboratory Animal Care" and the 
"Guide for the Care and Use of Laboratory Animals" 
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(National Institutes of Health Publication No. 80-23, 
revised 1985). 
Specimen harvesting and preparation 
All animals were anaesthetised with intravenous thi- 
amylal sodium (60 mg/kg), intubated, and ventilated 
with 33% oxygen. Unilateral or both external jugular 
veins were exposed through a midline neck incision. 
A total of 43 veins, with a length of about 10 cm, were 
harvested from the 30 dogs, and divided into two 
groups: group I, for assay of PGI 2 production; group 
II, for implantation study. Both groups included the 
following four subgroups according to the type of 
treatment added to the veins: subgroup A, freshly 
harvested veins used as control; subgroup B, veins 
placed in dishes and rinsed repeatedly with hep- 
arinised saline for 120 min at room temperature; sub- 
group C, veins frozen (without cryoprotective agents 
and a programmed freezer) and cryopreserved in a 
heparinised saline at - 80 °C for 1-3 months; subgroup 
D, veins treated with a RPMI-1640 solution (The Re- 
search Foundation for Microbial Diseases of Osaka 
University, Japan) containing 1000units/ml dispase 
(Godo Shusei Co., Ltd., Japan) for i h at 37 °C. 
In group I, 27 veins from 14 dogs were used. Each 
vein harvested was immediately rinsed with phos- 
phate-buffered saline (PBS; pH 7.4), and after excision 
of excessive surrounding tissue, the vein was opened 
longitudinally. The veins in subgroup I-A were im- 
mediately submitted to the process of PGI 2 assay, while 
the veins in subgroups I-B, C and D were added to 
each treatment. After the treatments, each vein was 
cut into 1 cm long segments; three were used for 
histomorphological study, while those remaining were 
subjected to assay of PGI 2 production. A total of 260 
segments were obtained from 27 veins. Of the 260, 
there were 188 available for assay of PGI 2 production, 
and the remaining 72 were used for hi- 
stomorphological examinations. 
In group II, these four types of veins from 16 dogs, 
which were treated in the same manner, were auto- 
genously implanted into the abdominal aortas of the 
same dogs. 
scanning electron microscopy (SEM), and light micro- 
scopy, respectively. 
The area of the endothelial cell coverage was as- 
sessed by the SNS, and the morphological changes 
regarding the viability were evaluated by later SEM. 
The segments for the SNS were mounted on a plate 
immediately after the treatments, and then submerged 
in 0.3% silver nitrate for 3 min. After completion of 
the SNS, the luminal surface was scanned under the 
stereomicroscope, and the area of endothelial cell cov- 
erage was determined by planimetry using an image- 
analysing system (Image, Machintosh®, Apple Com- 
puter Inc., U.S,A.). The segments for SEM were fixed 
with 1% glutaraldehyde, dehydrated in a graded t- 
butyl alcohol series, dried in a freeze-dryer, and coated 
with platinum before examination. The histo- 
pathological changes in the media and the adventitia 
were evaluated by light microscopy, and the sections 
were stained with haematoxylin and eosin (HE), Elast- 
ica van Gieson, and Masson trichrome methods. 
Preparation and method for radioimmunoassay of PGI 2 
production 
PGI 2 production was measured by radioimmunoassay 
for the basal and arachidonic acid (AA) stimulated 
segments as its stable metabolite, 6-keto-prostaglandin 
F 1~ (PGFI~), using a I~25-6-keto-PGF 1~ kit (New England 
Nuclear Research Products, Boston, U.S.A.). Each seg- 
ment for the basal 6-keto-PGF ~production was placed 
in an incubation well containing 1.0 ml of Tris/NaC1/ 
buffer (pH 7.4), and incubated in a shaker for 5 min at 
37 °C; each segment used for the stimulated production 
was placed into the well containing the 1.0ml in- 
cubation medium, to which 25 ~tmol/1 AA had been 
added, and then incubated, using the same method 
as the basal production. After incubation, each segment 
was quickly removed from the incubation well, and 
indomethacin (200 ~tg/ml) was added. The remaining 
fluid was frozen at -80  °C for later assay, while the 
segment removed was placed in a heat chamber for 
24 h at 100 °C, and the dry weight was obtained. Values 
for 6-keto-PGF 1~ were expressed as picograms of 
immunoreactive 6-keto-PGF h per mg of dry vein tissue 
per min. The mean value of the dry weights was 
10.4 + 0.22 mg (mean + s.E.). 
HistomorphologicaI evaluation 
In order to confirm the pathological sequences in the 
veins by the treatments, three segments obtained from 
each vein were used for silver nitrate staining (SNS), 
Implantation study 
In group II, four types of the vein grafts were auto- 
genously implanted into the aortas of dogs by end-to- 
end anastomosis, using 7-0 polypropylene sutures. 
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Although eparin (100 IU/kg) was administered intra- 
venously at implantation and prior to sacrifice, neither 
antiplatelet agents nor anticoagulants were given dur- 
ing the observation period. 
After 24 h, the dogs were anaesthetised again, and 
fully heparinised. After the graft patency was assessed 
by palpation, euthanasia solution was administered 
intravenously. All grafts, including both anastomoses, 
were carefully retrieved, and their anti- 
thrombogenicity was assessed by both macroscopic 
inspection and a measuring of the percentage of the 
thrombus-free surface area called the thrombus-free 
surface (TFS) score, a technique previously reported 
by Sauvage et al. 5 The area of TFS was traced on 
the photograph, and the TFS score was obtained by 
planimetry using the computer image analysis ystem. 
Statistical analysis 
All data were expressed as mean + one standard error 
(s.E.), and were analysed with a StatView software 
package (Avacus Concepts, Inc., Berkley, CA, U.S.A.). 
The Kruskal-Wallis test (non-parametric ANOVA), 
and subsequent multiple comparison through the 
Mann-Whitney U-test were used to determine dif- 
ferences between values of 6-keto-PGF 1~, and between 




In subgroup I-A, the SNS and the SEM revealed an 
intact endothelial cell lining, and light microscopy 
showed normal SMCs in the media (Fig. la). A few 
fibrocytes were recognised in the adventitia. In sub- 
group I-B, complete ndothelial denudation and con- 
sequent exposure of the internal elastic lamina were 
recognised, whereas the integrity of the media and 
the adventitia were well-preserved (Fig. lb). In sub- 
groups I-C and D, complete ndothelial denudation 
and degenerative changes in the medial SMCs, such 
as karyopycnosis or karyolysis, were observed. The 
internal elastic lamina and connective tissue in the 
media were intact in subgroup I-C (Fig. lc); in sub- 
group I-D, there was severe damage and desquamation 
of the internal elastic lamina, followed by exposure 
of underlying fibrous tissue and karyopycnosis with 
eosinophilic change of cytoplasma inthe medial SMCs, 
revealing a deep injury in the vein wall (Fig. ld). 
Prostacyclin production 
As shown in Table 1, the levels of production in 
subgroup A were significantly higher in both a basal 
and a stimulated state than those in the other three 
subgroups (p<0.01 for basal, p<0.01 for stimulated), 
while the veins in subgroup I-B generated a substantial 
amount of 6-keto-PGF 1~ for both states when compared 
with those in subgroups I-C and D (p<0.05 for basal, 
p<0.05 for stimulated), suggesting the significance of 
PGI 2 production by the SMCs. The existence of re- 
sponses by AA stimulation in subgroups I-C and D 
suggested that these segments till contained a few 
viable cells generating a small amount of PGF. 
As shown in Fig. 2, both models in subgroups II-A 
and B showed good antithrombogenicity, although the 
antithrombogenicity of the models in subgroups II-C 
and D was markedly reduced. This was especially 
true in subgroup II-D, in which a thick platelet-rich 
thrombus occupied the entire flow surface, and two 
of the grafts were failing. Mean TFS scores in sub- 
groups II-A through D were 98 ± 2%, 90 -t- 2%, 38 + 5%, 
and 15 + 7%, respectively; the veins in subgroup II-B as 
well as in II-A showing significant antithrombogenicity 
when compared with those in subgroups II-C and D 
(p=0.014) (Table 2). This result suggested that the 
amount of PGI 2 generated by the medial SMCs is 
sufficient for maintaining the antithrombogenicity of 
the endothelial denuded vein grafts, while the anti- 
thrombogenic property almost entirely disappeared 
when the SMC function was lost. The TFS score in 
subgroup II-C was significantly higher than that in 
subgroup II-D (p = 0.014), demonstrating that the intact 
extracellular components of the vein grafts without 
the cell function still maintained a relative, though not 
particularly significant, antithrombogenicity. 
Discussion 
While there is no doubt that endothelial cells play the 
most important role in the excellent anti- 
thrombogenicity of AVGs, because of their PGI 2 pro- 
duction 6-8 and fibrinolytic activity, 9'1° it is an undeniable 
fact that de-endothelialised AVGs in the early phase 
after implantation also maintain their patency until 
endothelial healing is largely accomplished. 2 This fact 
suggests that AVGs have some antithrombogenic fa - 
tors, in addition to PGI 2 production and fibrinolytic 
activity of the endothelial cells, which seem to play 
an important role in the antithrombogenicity and pat- 
ency at an early phase after implantation. It has been 
reported that medial SMCs of arteries may produce 
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Fig. 1. Light micrographs (LM, HE x 800) of the control and the treated veins in group I. (a) Subgroup I-A (control): LM (cross section), 
showing complete ndothelial cell coverage (black arrows) and intact medial smooth muscle c lls. (b) Subgroup I-B: LM (longitudinal 
section), showing complete ndothelial denudation and the intact integrity of the media and the adventitia. (c) Subgroup I-C: LM (cross 
section), noting degenerative changes in the medial SMCs, such as karyopycnosis (white arrows) or karyolysis (black arrows). The internal 
elastic lamina nd connective tissue in the media are intact. (d) Subgroup I-D: LM (cross section), showing karyopycnosis (white arrows) 
with eosinophilic changes of cytoplasma (black arrows) in the medial SMCs. L=luminal surface. M=media. A=adventitia. 
Table 1. 6-keto-PGF 1~ production for a basal and a stimulated state in treated vein segments. 
No. of vein Basal No. of vein Stimulated 
segments production segments production 
Subgroup I-A (n = 21) 58.0 ± 8.9* (n = 21) 530.6 +_ 74.7f 
Subgroup I-B (n = 22) 26.3 ± 4.7** (n = 22) 82.3 ± 11.4tq- 
Subgroup I-C (n =30) 17.9 ± 1.3 (n =30) 39.4 +3.3 
Subgroup I-D (n = 21) 13.3 ±1.8 (n = 21) 32.3 ± 6.2 
Values are means ± s.c. 
* p<0.01 vs. subgroups 
f p<0.01 vs. subgroups 
expressed as pg/min/mg DW. 
I-B, C and D, ** p<0.05 vs. subgroups 
I-B, C and D, +t p<0.05 vs. subgroups 
I-C and D at basal state. 
I-C and D at stimulated state. 
PGI2, m12 and further studies have indicated that cul- 
tured SMCs d isp layed biosynthet ic  activity of PGI2} 3-1s 
These reports suggest he presence of PGI 2 product ion  
by  the media l  SMCs also in AVGs; however,  it still 
remains  unclear  whether  the amount  of PGI 2 is effect- 
ive in ma inta in ing  the ant i thrombogenic i ty  and  pat- 
ency. Therefore, it is necessary to conduct  further 
studies in order to clarify the signif icance of the PGI 2 
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Fig. 2. Luminal surface of retrieved vein grafts 24 h after implantation in group I]. (a) Subgroup II-A: there was almost no detectable 
thrombi along the graft length. (b) Subgroup II-B: a small amount of thrombi, mostly at the valves, was recognised. (c) Subgroup II-C: 
the area of thrombus deposition was markedly extended. (d) Subgroup II-D: a thick platelet-rich thrombus occupied the entire flow 
surface. The black arrow indicates proximal anastomosis and the white arrow distal anastomosis. 
Table 2. Thrombus free surface (TFS) score of treated vein grafts 
24 h after implantation. 
No. of grafts TFS score (%) 
Subgroup II-A (n =4) 98 +2* 
Subgroup II-B (n = 4) 90 + 2t 
Subgroup II-C (n =4) 38 +5# 
Subgroup II-D (n =4) 15 _+ 7 
Values are means ± s.m; TFS score = (total area of flow surface- area 
covered by thrombus)/total area of flow surface x 100; * p=0.014 
vs. subgroups II-C and D; fp=0.014 vs. subgroups II-C and D; 
#p=0.014 vs. subgroup II-D. 
production, and thus an implantation study in com- 
bination with PGF assay for endothelial denuded 
AVGs is essential. 
In order to accomplish endothelial denudation, vari- 
ous methods uch as air-drying, 16 rubbing the luminal 
surface, ~7 or enzymatic digestion using trypsin ~shave 
been reported; however, these methods may damage 
the medial layer as well as the endothelium. Angelini 
et al. 19 reported that PGI 2 production from freshly 
isolated veins was not reduced after storage for 2 h in 
isotonic saline, while LoGerfo et al. 3 described how a 
large area of endothel ium was disrupted by storage 
for i h. Hence, in order to attain selectively the entire 
endothelial denudation, we employed the method of 
a 2-hour storage with intermittent rinsing in a hep- 
arinised saline, which provided the complete endo- 
thelial denudation and dysfunction without any 
obvious medial injury. 
Previous studies have demonstrated that the internal 
elastic lamina, which is exposed due to endothelial 
desquamation, showed excellent antithrombogenicity 
in the preserved human umbilical vein grafts} °m 
Hence, in order to assess the independent anti- 
thrombogenic function of the medial SMCs, it is also 
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necessary to clarify the intrinsic antithrombogenicity 
of the internal elastic lamina of the vein grafts, and 
thus the acellular graft models with or without pre- 
servation of the internal elastic lamina were provided. 
In subgroup C, in order to obtain the vein grafts in 
which the internal elastic lamina was intact and all of 
the cells were killed, we employed a simple freeze 
method followed by cryopreservation. Living mam- 
malian cells frozen without cryoprotective agents or 
a programmed freezer generally suffer severe injury 
to the cell membrane, resulting in the destruction of 
cells, 22"a3 while the integrity of the extracellular matrix is 
preserved. 24'25 The histomorphological findings before 
implantation obtained from the vein grafts in subgroup 
C coincided with those results. The results of the 
present study suggested that the antithrombogenicity 
of the vein grafts was significantly impaired when 
accompanied by dysfunction of the medial SMCs, even 
though the integrity of the extracellular matrix was 
intact. The SEM and the light microscopy revealed 
that the internal elastic lamina of veins is thin and not 
uniform, and has extensive and multiple defects when 
compared with those of the internal thoracic artery 26 
or the human umbilical vein. 21 Accordingly, in addition 
to the cell dysfunction, the intrinsically poor quality of 
the internal elastic lamina might result in the excessive 
thrombus deposition in the cryopreserved vein grafts 
in subgroup C. 
Several studies have demonstrated that the anti- 
thrombogenicity was markedly impaired by treatment 
with trypsin 27-29 as well as by cryopreservation. Mand- 
erson et aL TM reported that injury by treatment with 
trypsin involved not only endothelium but the medial 
layer. In subgroup D, we employed a despase treat- 
ment to produce the vein grafts with removal of the 
internal elastic lamina, which resulted in a severe 
thrombus deposition. The results of subgroups II-C 
and D suggested that the internal elastic lamina itself 
may have a preferable antithrombogenicity. 
The differences between the 6-keto-PGF l~ levels in 
both a basal and a stimulated state in subgroups I-A 
and B demonstrated that the capacity of endothelial 
cells to produce PGI 2 is markedly greater than that of 
SMCs, 19 whereas the increase in release of 6-keto-PGF l~ 
by AA stimulation in subgroup I-B showed that the 
capacity of SMCs to produce PGI 2 was also significant. 
Likewise, the existence of responses by AA stimulation 
in the vein segments with cell dysfunction suggested 
that these segments till contained a few viable cells 
generating a small amount of PGI2; however, the thick 
thrombus deposition observed in the vein grafts of 
subgroups II-C and D suggested that those amounts 
of PGI 2 are not sufficient for maintaining the anti- 
thrombogenic effect. 
In order to protect he integrity of the endothelium 
and the medial layer, various preparation techniques 
such as the use of papaverine, 3'3° autogenous hep- 
arinised blood 4 as the medium for preparation, or 
distension at a lower luminal pressure 31'32 have been 
described, while the levels of denudation in AVGs 
vary from report to report. The variation may be 
caused by the differences in the evaluation method as 
well as in the implantation period. In clinical use of 
AVGs, the risk of further injury is much greater than 
with experimental use. The ischaemia time during 
preparation and grafting procedure is longer, and 
subsequent exposure to arterial blood flow must result 
in extensive endothelial desquamation due to re- 
perfusion injury 33 in addition to the high shear stress. 
Nevertheless, our results have shown that those op- 
timal techniques for preparation play an important 
role in protection of the functional integrity of SMCs 
rather than that of endothelial cells, which were de- 
nuded in the early phase after implantation. 
In conclusion, endothelial denuded AVGs produced 
a significant amount of PGI 2. Additional elimination 
of the medial SMC function in AVGs resulted in the 
further significant decrease in PGF production, and in 
the implantation study using such AVGs, extensive 
thrombus deposition was observed. Hence, we con- 
clude that the amount of PGI 2 generated by the medial 
SMCs may be sufficient for maintaining the anti- 
thrombogenicity of the endothelial denuded vein 
grafts, and attention should be paid to the protection 
of th e viability and function of the medial SMCs rather 
than to that of the endothelial cells. 
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